Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1)

Inclusion Criteria:

• Adults, 18 to 80 years of age
• Meets diagnostic criteria for isolated CD (idiopathic; dystonic symptoms localized tothe head, neck, shoulder areas) with at least moderate severity at Baseline (Day 1),defined as a TWSTRS-total score of at least 20, with at least 15 on theTWSTRS-Severity subscale, at least 3 on the TWSTRS-Disability subscale, and at least 1on the TWSTRS-Pain subscale

Exclusion Criteria:

• Cervical dystonia attributable to an underlying etiology, (e.g., traumatic torticollisor tardive torticollis)
• Predominant retrocollis or anterocollis CD
• Significant dystonia in other body areas, or is currently being treated with BoNT fordystonia in areas other than those associated with isolated CD
• Severe dysphagia (Grade 3 or 4 on the Dysphagia Severity Scale) at Screening orBaseline (prior to study treatment)
• Any neuromuscular neurological conditions that may place the subject at increased riskof morbidity with exposure to BoNT, including peripheral motor neuropathic diseases (e.g., amyotrophic lateral sclerosis and motor neuropathy, and neuromuscularjunctional disorders such as Lambert-Eaton syndrome and myasthenia gravis)
• Previous treatment with any BoNT product for any condition within the 14 weeks priorto Screening
• Botulinum Neurotoxin Type A (BoNTA), except the investigational daxibotulinumtoxinA,treatment-experienced subjects who had suboptimal or no treatment response to the mostrecent BoNTA injection for CD, as determined by the investigator, or history ofprimary or secondary non-response to BoNTA injections, known to have neutralizingantibodies to BoNTA; or have a history of botulinum toxin type B (rimabotulinumtoxinB [Myobloc/Neurobloc]) injection for CD due to non-response or suboptimal response toBoNTA